<DOC>
	<DOCNO>NCT02512068</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety SYR-472 administer dose 25 mg weekly use placebo control patient type 2 diabetes mellitus complicate severe renal impairment end-stage renal failure inadequate glycemic control despite diet and/or exercise therapy ( give ) despite treatment one antidiabetic drug addition diet and/or exercise therapy ( give ) ; evaluate long-term efficacy safety SYR-472 administer dose 25 mg weekly patient type 2 diabetes mellitus complicate severe renal impairment end-stage renal failure .</brief_summary>
	<brief_title>A Phase 3 , Randomized , Double-blind , Parallel-group , Comparative Study Phase 3 , Multicenter , Open-label , Long-term Study SYR-472 ( 25 mg ) Patients With Type 2 Diabetes Mellitus Complicated Severe Renal Impairment End-stage Renal Failure</brief_title>
	<detailed_description>This phase 3 , multicenter , randomize , double-blind , parallel-group , comparative study ( Treatment Period I ) phase 3 , multicenter , open-label , long-term study ( Treatment Period II ) use placebo control evaluate efficacy safety SYR-472 administer orally dose 25 mg weekly patient type 2 diabetes mellitus complicate severe renal impairment end-stage renal failure inadequate glycemic control despite diet and/or exercise therapy ( give ) despite treatment one antidiabetic drug addition diet and/or exercise therapy ( give ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1 . The participant diagnosis type 2 diabetes mellitus . 2 . The participant fasting Cpeptide level 0.6 ng/mL high start screen period ( Week 6 ) Week 2 screening period . 3 . The participant hemoglobin value 10.0 g/dL high start screen period ( Week 6 ) Week 2 screening period . 4 . The participant HbA1c value 7.0 % high less 10.0 % Week 2 screening period , unless participant undergoing hemodialysis ( Patients Endstage Renal Failure ) HbA1c value le 7.0 % Week 2 glycated albumin value 20 % high . 5 . The participant HbA1c value 7.0 % high less 10.0 % Week 2 The participant HbA1c value difference start screen period ( Week 6 ) Week 2 screening period within 10.0 % * HbA1c value start screen period ( Week 6 ) . The participant undergoing hemodialysis ( Patients Endstage Renal Failure ) HbA1c value le 7.0 % Week 2 glycated albumin value 20 % high . The difference glycated albumin value start screen period ( Week 6 ) Week 2 10 % * le glycated albumin value Week 6 . * : round one decimal place 6 . The participant fix diet and/or exercise therapy ( give ) least 6 week prior start screen period ( Week 6 ) . 7 . The participant meet follow : The participant receive antidiabetic medication ( include insulin preparation ) least 6 week prior start screen period ( Week 6 ) . The participant treat one oral hypoglycemic drug* start least 6 week prior start screen period ( Week 6 ) fix dose regimen . * : one follow medication : mitiglinide calcium hydrate , repaglinide , acarbose , miglitol , voglibose The participant treat one insulin preparation** start least 6 week prior start screen period ( Week 6 ) fix dose regimen ( ≤40 units/day ) insulin preparation . Any one follow insulin monotherapies : mixed ( rapidacting shortacting insulin contain 30 % volume ) , intermediateacting , longacting soluble insulin preparation 8 . The participant undergoing hemodialysis peritoneal dialysis severe renal impairment [ creatinine clearance ( Ccr ) &lt; 30 mL/min start screen period ( Week 6 ) ] , participant undergoing hemodialysis endstage renal failure . 9 . In opinion investigator subinvestigator , initiation hemodialysis peritoneal dialysis least within 12 week start investigational product expect . [ case participant undergoing hemodialysis peritoneal dialysis ( patient severe renal impairment ) ] 10 . The participant undergoing hemodialysis start least 6 month prior inform consent , opinion investigator subinvestigator , participant clinically stable . [ case participant undergoing hemodialysis ( patient endstage renal failure ) ] 11 . The participant male female age 20 year old time inform consent . 12 . A female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent one month end study . 13 . In opinion investigator subinvestigator , participant capable understand comply protocol requirement . 14 . The participant sign date write , informed consent form prior initiation study procedure . 1 . The participant clinically evident hepatic impairment [ e.g. , AST ALT ≥2.5 time upper limit normal total bilirubin ≥2.0 mg/dL start screen period ( Week 6 ) Week 2 screening period ] . 2 . The participant serious cardiac disease , cerebrovascular disorder , serious pancreatic hematological disease ( e.g. , participant require inpatient treatment hospitalize treatment within 24 week prior start screen period ) . 3 . The participant severe ketosis , diabetic coma pre coma , type 1 diabetes , severe infection , surgery , severe external injury . 4 . The participant hemoglobinopathy ( sickle cell disease , thalassemia , etc. ) . 5 . The participant experience hypoglycemia ( participant blood glucose level ≤70 mg/dL hypoglycemic symptom ) within 6 week prior start screen period screen period ( least twice per week ) . 6 . The participant inadequately control hypertension . 7 . For participant treat one antidiabetic agent , participant use least two antidiabetic therapy day 6 week prior start screen period ( Week 6 ) ( 43 day prior start screen period ) . 8 . The participant malignancy . 9 . The participant history hypersensitivity allergy dipeptidyl peptidase 4 ( DPP4 ) inhibitor . 10 . The participant history gastrectomy small intestinal resection . 11 . The participant habitual drinker consumes daily average 100 mL alcohol . 12 . The participant history drug abuse ( define use illegal drug ) alcohol dependence . 13 . The participant require take excluded medication study period . 14 . The participant receive SYR472 previous clinical study . 15 . The participant receive investigational product ( include study drug postmarketing clinical study ) within 12 week prior start screen period . 16 . The participant participate clinical study time inform consent . 17 . If female , participant pregnant lactate intend become pregnant time inform consent within 1 month end study ; intend donate ova time period . 18 . The participant immediate family member , study site employee , dependent relationship study site employee involve conduct study ( e.g. , spouse , parent , child , sibling ) may consent duress . 19 . The participant hospitalized screening period deem require hospitalization study period investigator subinvestigator , unless hospitalization shortterm evaluation include complete health checkup shunt ( include shunt maintenance ) . 20 . The participant deem ineligible study reason investigator subinvestigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>